Recurrence of pseudomyxoma peritonei after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Fiche publication
Date publication
avril 2019
Journal
BJS open
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BRIGAND Cécile
Tous les auteurs :
Mercier F, Dagbert F, Pocard M, Goéré D, Quenet F, Wernert R, Dumont F, Brigand C, Passot G, Glehen O,
Lien Pubmed
Résumé
Pseudomyxoma peritonei (PMP) is a rare clinical condition characterized by mucinous ascites, typically related to appendiceal or ovarian tumours. Current standard treatment involves cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), but recurrences occur in 20-30 per cent of patients. The aim of this study was to define the timing and patterns of recurrence to provide a basis for modifying follow-up of these patients.
Mots clés
Adult, Aged, Combined Modality Therapy, methods, Cytoreduction Surgical Procedures, methods, Disease-Free Survival, Female, Follow-Up Studies, Humans, Hyperthermia, Induced, methods, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Recurrence, Local, diagnosis, Peritoneal Neoplasms, mortality, Peritoneum, pathology, Prognosis, Prospective Studies, Pseudomyxoma Peritonei, mortality, Retrospective Studies, Time Factors
Référence
BJS Open. 2019 04;3(2):195-202